Serina Therapeutics Files Q1 2025 10-Q
Ticker: SER · Form: 10-Q · Filed: May 8, 2025 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Serina Therapeutics Q1 2025 10-Q is in. Check financials.
AI Summary
Serina Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as AgeX Therapeutics, Inc., reported financial results for the first quarter of 2025. Key personnel include CEO Steve Ledger and CFO Gregory Curhan.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Serina Therapeutics, Inc. during the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Serina Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial results)
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Filer of the 10-Q
- AgeX Therapeutics, Inc. (company) — Former name of Serina Therapeutics, Inc.
- Steve Ledger (person) — Chief Executive Officer and Director
- Gregory Curhan (person) — Chief Financial Officer
- 20250331 (date) — End of reporting period
FAQ
What were Serina Therapeutics' grant revenues for the first quarter of 2025?
The filing indicates grant revenues for the period January 1, 2025 to March 31, 2025, but the specific dollar amount is not detailed in this header information.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
When was Serina Therapeutics formerly known as AgeX Therapeutics, Inc.?
The date of the name change was June 6, 2017.
Who is the Chief Development Officer?
Randall Moreadith is listed as the Chief Development Officer.
What is the company's SIC code?
The Standard Industrial Classification code is 2834, Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 by Steve Ledger regarding Serina Therapeutics, Inc. (SER).